Micafungin treatment and eradication of candiduria among hospitalized patients.

Abstract

In high-risk patients, candiduria may be associated with the development of urinary tract infections (UTI) and invasive candidiasis. The triazole antifungals achieve good urine concentrations, but their use is limited by the emergence of non-albicans Candida spp. with low-triazole susceptibility. The echinocandins remain fungicidal against many azole-resistant Candida spp., but low urine concentrations limit their use. We examined the rates of candiduria elimination in micafungin-treated patients. This retrospective analysis evaluated consecutive patients with candiduria (1/2008-4/2011) who were treated with micafungin (100mg/day) and had post-micafungin urine cultures. Patients were deemed to have either candiduria or UTI and were assessed for short-term (within 2weeks post-micafungin) and long-term (>1month post-micafungin) urine sterilization. Thirty-three patients meeting our inclusion criteria were identified. Of these, 16 (48%) were diagnosed with a Candida UTI. A total of 25 patients (76%) had Foley catheters, which were replaced in 11 (44%) cases. The majority of patients had Candida albicans (39%), but Candida krusei and Candida glabrata (33%) were also isolated. Eight patients (24%) were immunocompromised, and 29 (88%) received broad-spectrum antibiotics. Rates of urine sterilization during micafungin treatment, 2weeks after micafungin, and>1month after micafungin were 81, 78, and 75%, respectively. Among hospitalized patients with candiduria, micafungin administration was frequently associated with both short- and long-term urine sterilization. This was observed among patients with or without Foley removal and among those with Candida albicans, as well as non-albicans Candida spp.